About ImmPACT-Bio
ImmPACT-Bio is a company based in Ness Ziona (Israel) founded in 2017 was acquired by Lyell Immunopharma in October 2024.. ImmPACT-Bio has raised $157.86 million across 3 funding rounds from investors including Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical. ImmPACT-Bio offers products and services including Bispecific CAR T Cells and TGF-β CAR.
- Headquarter Ness Ziona, Israel
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immpact Bio, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$157.86 M (USD)
in 3 rounds
-
Latest Funding Round
$8 M (USD), Grant
Feb 29, 2024
-
Investors
Lyell Immunopharma
& 13 more
-
Employee Count
Employee Count
-
Acquired by
Lyell Immunopharma
(Oct 24, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmPACT-Bio
ImmPACT-Bio offers a comprehensive portfolio of products and services, including Bispecific CAR T Cells and TGF-β CAR. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Bispecific CAR T cells are employed to prevent antigen escape in cancer and autoimmune diseases
TGF-β CAR is utilized to rewire T cell responses against immunosuppressive microenvironments in cancer
Unlock access to complete
Unlock access to complete
Funding Insights of ImmPACT-Bio
ImmPACT-Bio has successfully raised a total of $157.86M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $8 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $8.0M
-
First Round
First Round
(18 Aug 2020)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Grant - ImmPACT-Bio | Valuation |
investors |
|
| Jan, 2022 | Amount | Series B - ImmPACT-Bio | Valuation | VenBio , Foresite Capital | |
| Aug, 2020 | Amount | Series A - ImmPACT-Bio | Valuation | Orbimed , Johnson & Johnson Innovation – JJDC |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ImmPACT-Bio
ImmPACT-Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science and technology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ImmPACT-Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ImmPACT-Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immpact-Bio Comparisons
Competitors of ImmPACT-Bio
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about ImmPACT-Bio
When was ImmPACT-Bio founded?
ImmPACT-Bio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is ImmPACT-Bio located?
ImmPACT-Bio is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Who is the current CEO of ImmPACT-Bio?
Merav Beiman is the current CEO of ImmPACT-Bio.
Is ImmPACT-Bio a funded company?
ImmPACT-Bio is a funded company, having raised a total of $157.86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Aug 18, 2020.
What does ImmPACT-Bio do?
ImmPACT-Bio was founded in 2017 and is based in Ness Ziona, Israel. Operations in the biotechnology sector are centered on the advancement of biological products and therapies. Research efforts are led by CEO Merav Beiman, with a focus on innovative medical solutions. Activities are conducted primarily in Israel, addressing needs in biopharmaceutical applications across various therapeutic areas. Limited details on specific services are available.
What products or services does ImmPACT-Bio offer?
ImmPACT-Bio offers Bispecific CAR T Cells and TGF-β CAR.
Who are ImmPACT-Bio's investors?
ImmPACT-Bio has 14 investors. Key investors include Lyell Immunopharma, Orbimed, Bukwang Pharmaceutical, venBio, and Foresite Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.